Biotech 10 February 2026 - 2 June 2026

Design Therapeutics Drops Ahead of Jefferies, Trial Remains in Focus for DSGN
····

Design Therapeutics Drops Ahead of Jefferies, Trial Remains in Focus for DSGN

Design Therapeutics shares slid on Tuesday afternoon, dropping 24 cents to $10.20 in a broader biotech selloff. The Carlsbad, California-based firm was off roughly 2.3%. The SPDR S&P Biotech ETF lost about 4.0%, and the iShares Nasdaq Biotechnology ETF slipped about 3.0%. Design shares are in focus again since there’s been no new trial data update. The most recent post on Design’s investor page is still the May 28 Jefferies conference notice. Management is slated for a fireside chat in New York on June 4 at 1:25 p.m. EDT.
June 2, 2026
Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote
·······

Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote

Ligand Pharmaceuticals shares moved higher on Tuesday. The stock outperformed biotech funds, which took a hit, as investors focused on upcoming management meetings and stayed active trading Ligand’s pending XOMA Royalty deal. The Nasdaq-listed stock was trading at $233.11 as of 12:53 p.m. EDT, up 1.4%. The SPDR S&P Biotech ETF was down 3.8% and the iShares Nasdaq Biotechnology ETF slid 3.0%. The SPY ETF, which tracks the S&P 500, edged up 0.1% and the QQQ, which follows the Nasdaq 100, added 0.4%.
June 2, 2026
Lakefront Biotherapeutics Shares Drop as LKFT Gets Reevaluated
····

Lakefront Biotherapeutics Shares Drop as LKFT Gets Reevaluated

Lakefront Biotherapeutics NV shares dropped 2.7% to 23.80 euros in Amsterdam on Monday. In New York, its Nasdaq ADRs were off 1.7% at $27.86 early in the afternoon. The Belgian biotech, which recently took the Lakefront name, has lost about 15% this year on both markets. Lakefront is still in the early days after its Galapagos rebrand. Shareholders okayed switching the name to Lakefront Biotherapeutics and adopted the new ticker LKFT. Management wants investors to now value it as a cash-heavy acquirer and builder of oncology and immunology programs, instead of focusing on the Galapagos legacy pipeline.
June 1, 2026
Werewolf Therapeutics Stock Stalls While HOWL Holds for Strategic Update
····

Werewolf Therapeutics Stock Stalls While HOWL Holds for Strategic Update

Werewolf Therapeutics stock traded near 45 cents Monday morning, holding close to its 52-week low on Nasdaq. Investors watching for updates on the company’s ongoing strategic review. Shares were flat in early trading, putting the company’s market cap near $22 million. The timing here is important because the most recent company-specific filing before this week wasn’t a trial update—it was an insider sale. A Form 4 filed after the bell Friday showed entities tied to director Luke Evnin dumped a total of 141,106 Werewolf shares between May 27 and May 29, using a Rule 10b5-1 plan, which lets insiders sell stock on a schedule.
June 1, 2026
Krystal Biotech Near Highs After Insider Filing Ahead of 2026 Data
····

Krystal Biotech Near Highs After Insider Filing Ahead of 2026 Data

Krystal Biotech was poised to start Thursday trade just below its 52-week high. A fresh SEC filing showed EVP and general counsel Thomas John Charles sold a small batch of shares using a preset trading plan. KRYS last traded at $306.63, above the midpoint of its $123.03 to $319.48 range for the past year. U.S. markets stayed open. Nasdaq’s 2026 calendar shows markets closed for Memorial Day on May 25 and Juneteenth on June 19. Thursday lands on a normal trading day after the short week.
May 28, 2026
Quince Therapeutics Stock Pauses After Volatile Biotech Moves
····

Quince Therapeutics Stock Pauses After Volatile Biotech Moves

Quince Therapeutics shares didn't move Monday as markets shut for Memorial Day. Investors were left with several updates from the small-cap biotech last week: a pipeline buy, plans for a sizable private funding, and a filing that lifted a short-term listing risk. Nasdaq will stay closed on Memorial Day again in 2026, which falls on May 25, according to its holiday calendar. Quince Therapeutics shares finished Friday at $1.10, rising 2.8% for the day on roughly 1.23 million shares traded, according to the company’s investor-relations page. The stock still posted a 4.3% drop for the week after closing at $1.15 the previous Friday, weighed by a choppy Monday after its Orphai Therapeutics news.
May 25, 2026
CSL shares under pressure as traders eye critical week
····

CSL shares under pressure as traders eye critical week

CSL Ltd starts Monday as traders weigh last week’s 18% fall. The drop followed a profit warning and a non-cash impairment of about $5 billion, a write-down that reduces asset values but has no instant cash impact. The ASX cash market is still shut after the weekend, with trading set to start around 09:59:45 Sydney time. CSL's slide is weighing on the market now, where it used to be a safe spot. CSL ended Friday at A$97.96, up 0.72% for the day, but down 18.3% across five sessions. The S&P/ASX 200 closed at 8,630.8, dropping 0.11% on Friday.
May 17, 2026
CSL Buyback Near 2017 Lows: Why the ASX Biotech Giant Is Under Pressure
···

CSL Buyback Near 2017 Lows: Why the ASX Biotech Giant Is Under Pressure

CSL Limited picked up another 110,004 shares on April 30, spending A$13.69 million, according to a May 1 ASX filing, as the biotech company keeps buying its own stock while trading close to multi-year lows. Up to that point, CSL had already repurchased 6,242,085 shares for a total of A$1.044 billion. The company previously announced the buyback could go as high as US$750 million and is set to continue until June 30. Timing matters here. CSL shares ended Friday at A$124.84, edging up 0.38%. Still, that's just above their 52-week low of A$123.88—less than half the 52-week high of A$275.79, according to market data.
May 3, 2026
CSL buyback hits 4 million shares as Australian biotech keeps buying after profit shock
···

CSL buyback hits 4 million shares as Australian biotech keeps buying after profit shock

CSL Ltd accelerated its on-market share buyback this Wednesday, snapping up 59,751 shares for A$8.57 million, according to an exchange filing. So far, the company has bought back 4.03 million shares, spending close to A$739 million under the buyback plan, which is capped at US$750 million. Persistent buying stands out, with CSL still working to calm investor nerves after its first-half earnings dropped and the company swapped leaders last month. Management is aiming for a stronger second half and stuck to its full-year guidance, while also bumping up its buyback.
March 5, 2026
Amgen stock slides as Kyowa Kirin halts rocatinlimab trials on cancer concerns
···

Amgen stock slides as Kyowa Kirin halts rocatinlimab trials on cancer concerns

New York, March 3, 2026, 13:41 ET — Regular trading hours Amgen Inc shares dropped $8.69, or 2.3%, to $377.01 as of 1:41 p.m. ET Tuesday, after Kyowa Kirin out of Japan pulled the plug on all current trials for its experimental drug rocatinlimab. The Japanese company had previously wrapped up its development and commercialization partnership with Amgen around rocatinlimab.
March 3, 2026